Cargando…
Safety and Efficacy of Pegvisomant in Pediatric Growth Hormone Excess
Objective: Pediatric growth hormone excess (GHE) and gigantism are mainly managed by pituitary surgery. However, a large percentage of patients require further medical management. Data for the pediatric population are scares and decisions are usually based on adult published data. We have initiated...
Autores principales: | Tatsi, Christina, Wajnrajch, Michael Paul, Camacho-Hubner, Cecilia, Stratakis, Constantine A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090719/ http://dx.doi.org/10.1210/jendso/bvab048.1321 |
Ejemplares similares
-
SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant
por: Wajnrajch, Michael, et al.
Publicado: (2019) -
MON-433 The Spectrum Of Growth Hormone Excess In Carney Complex: Characterizing A Common Finding In A Rare Syndrome
por: Tatsi, Christina, et al.
Publicado: (2019) -
SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience
por: Wajnrajch, Michael, et al.
Publicado: (2019) -
ODP618 The profile of patients with ACTH-secreting pituitary adenomas and subclinical pituitary apoplexy
por: Tatsi, Christina, et al.
Publicado: (2022) -
OR23-06 Is the Improved Glucose Homeostasis in Patients with Acromegaly Treated with Pegvisomant Caused by Improved Glucagon Secretion?
por: Jørgensen, miss, Nanna Thurmann, et al.
Publicado: (2020)